Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment

References

• Bhandare N, Narayana A. Applications of nanotechnology in cancer: a literature review of imaging and treatment. J Nuclear Med Rad Ther. 2014;5:195.
   Google Scholar
• Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Dis. Today. 2012;17:1044–1052.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. Can J Clinic. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Dis Today. 2010;15:842–850.
   PubMed Web of Science ®Google Scholar
• Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–2953.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clinical Oncol. 2009;6:718–730.
   PubMed Web of Science ®Google Scholar
• Lacey JV, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutag. 2002;39:82–88.
   PubMed Web of Science ®Google Scholar
• Plodinec M, Loparic M, Monnier CA. et al. The nanomechanical signature of breast cancer. Nature Nanotechnol. 2012;7:757–765.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men. Cancer. 2004;101(1):51–57.
   PubMed Web of Science ®Google Scholar
• Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arc Pathol Lab Med. 2009;133(4):611–612.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Decuzzi P, Cristofanilli M, et al. Nanotechnology for breast cancer therapy. Biomedical Microdev. 2009;11(1):49–63.
   PubMed Web of Science ®Google Scholar
• Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Nat Compreh Cancer Net. 2011;9(2):136–222.
   PubMed Web of Science ®Google Scholar
• Benson JR, Jatoi I, Keisch M, et al. Early breast cancer. Lancet. 2009;373(9673):1463–1479.
   PubMed Web of Science ®Google Scholar
• El Saghir NS, Eniu A, Carlson RW, et al. Locally advanced breast cancer. Cancer. 2008;113(S8):2315–2324.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. New Eng J Med. 2012;366(6):520–529.
   PubMed Web of Science ®Google Scholar
• Engel RH, Kaklamani VG. HER2-positive breast cancer. Drugs. 2007;67(9):1329–1341.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–5391.
   PubMed Web of Science ®Google Scholar
• Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Nat Can Inst. 2008;100(20):1439–1447.
   PubMedGoogle Scholar
• Brockhausen I. Mucin‐type O‐glycans in human colon and breast cancer: glycodynamics and functions. EMBO Reports. 2006;7(6):599–604.
   PubMed Web of Science ®Google Scholar
• Goshen R, Chu W, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast–ovarian cancer syndrome? Gynecol Oncol. 2000;79(3):477–481.
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161–171.
   PubMed Web of Science ®Google Scholar
• Shapira A, Livney YD, Broxterman HJ, et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011;14(3):150–163.
   PubMed Web of Science ®Google Scholar
• Grobmyer SR, Morse DL, Fletcher B, et al. The promise of nanotechnology for solving clinical problems in breast cancer. J Surg Oncol. 2011;103(4):317–325.
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Torchilin V, Patri AK, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res. 2012;18(12):3229–3241.
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Eddaoudi A, Davies D, et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69(10):4134–4142.
   PubMed Web of Science ®Google Scholar
• Chariou PL, Lee KL, Wen AM, et al. Detection and imaging of aggressive cancer cells using an epidermal growth factor receptor (EGFR)-targeted filamentous plant virus-based nanoparticle. Bioconjug Chem. 2015;26(2):262–269.
   PubMed Web of Science ®Google Scholar
• Nie S, Xing Y, Kim GJ, et al. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257–288.
   PubMed Web of Science ®Google Scholar
• Kwon IK, Lee SC, Han B, et al. Analysis on the current status of targeted drug delivery to tumors. J Control Release. 2012;164(2):108–114.
   PubMed Web of Science ®Google Scholar
• Yamashita F, Hashida M. Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev. 2013;65(1):139–147.
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.
   PubMed Web of Science ®Google Scholar
• Azagury A, Khoury L, Enden G, et al. Ultrasound mediated transdermal drug delivery. Adv Drug Deliv Rev. 2014;72:127–143.
   PubMed Web of Science ®Google Scholar
• Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed. 2005;1(3):193–212.
   PubMed Web of Science ®Google Scholar
• Nguyen KT. Targeted nanoparticles for cancer therapy: promises and challenges. J Nanomed Nanotechnol. 2011;2(5):1000103e.
   Google Scholar
• Dwivedi M, Kemp EH, Laddha NC, et al. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. Autoimmun Rev. 2015;14(1):49–56.
   PubMed Web of Science ®Google Scholar
• Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials. 2013;34(4):1270–1280.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2015;34(27):3547–3555.
   PubMed Web of Science ®Google Scholar
• Mo R, Jiang T, Gu Z. Enhanced anticancer efficacy by ATP‐mediated liposomal drug delivery. Angew Chem Int Ed. 2014;53(23):5815–5820.
   PubMed Web of Science ®Google Scholar
• Hrubý M, Filippov SK, Štěpánek P. Smart polymers in drug delivery systems on crossroads: Which way deserves following? Eur Polym J. 2015;65:82–97.
   Web of Science ®Google Scholar
• Loo C, Lowery A, Halas N, et al. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005;5(4):709–711.
   PubMed Web of Science ®Google Scholar
• Sinha R, Kim GJ, Nie S, et al. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5(8):1909–1917.
   PubMed Web of Science ®Google Scholar
• Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res. 200841(12):1842–1851.
   PubMed Web of Science ®Google Scholar
• Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem. 2006;384(3):620–630.
   PubMed Web of Science ®Google Scholar
• Salzano G, Zappavigna S, Luce A, et al. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth. J Biomed Nanotechnol. 2016;12(4):811–830.
   PubMed Web of Science ®Google Scholar
• Avci CB, Kurt CC, Tepedelen BE, et al. Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells. Tumor Biol. 2016;37(5):6673–6679.
   PubMed Web of Science ®Google Scholar
• Kopecka J, Porto S, Lusa S, et al. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget. 2016;7(15):20753.
   PubMed Web of Science ®Google Scholar
• Murphy SF, Varghese RT, Lamouille S, et al. Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide. Cancer Res. 2016;76(1):139–149.
   PubMed Web of Science ®Google Scholar
• Sultana S, Khan MR, Kumar M, et al. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review. J Drug Target. 2013;21(2):107–125.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–1467.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–2269.
   PubMed Web of Science ®Google Scholar
• Yuzhakova DV, Shirmanova MV, Sergeeva TF, et al. Immunotherapy of Cancer. Med Technol Med. 2016;8(1):173–181.
   Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
   PubMed Web of Science ®Google Scholar
• Cuenca AG, Jiang H, Hochwald SN, et al. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107(3):459–466.
   PubMed Web of Science ®Google Scholar
• Sahu SK, Mallick SK, Santra S, et al. In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery. J Mater Sci Mater Med. 2010;21(5):1587–1597.
   PubMed Web of Science ®Google Scholar
• Conde J, Doria G, Baptista P. Noble metal nanoparticles applications in cancer. J Drug Deliv. 2011;2012(2012):1–12.
   Google Scholar
• Jannesari M, Varshosaz J, Morshed M, et al. Composite poly (vinyl alcohol)/poly (vinyl acetate) electrospun nanofibrous mats as a novel wound dressing matrix for controlled release of drugs. Int J Nanomed. 2011; (6):993–1003.
   PubMedGoogle Scholar
• Wang J, Chen BA, Cheng J, et al. Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomedicine. 2011;6:1027–1034.
   PubMed Web of Science ®Google Scholar
• New RRC. Liposomes: a practical approach. Oxford: Oxford University Press; 1990.
   Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160.
   PubMed Web of Science ®Google Scholar
• Bawarski WE, Chidlowsky E, Bharali DJ, et al. Emerging nanopharmaceuticals. Nanomed. 2008;4(4):273–282.
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–IN27.
   PubMed Web of Science ®Google Scholar
• Bangham AD. Liposomes: the Babraham connection. Chem Phys Lipids. 1993;64(1):275–285.
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Gnad-Vogt SU, Beyer U, et al. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs. 2005;16(7):691–707.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet. 2003;42(5):419–436.
   PubMed Web of Science ®Google Scholar
• Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59(1):177–187.
   PubMed Web of Science ®Google Scholar
• Krieger ML, Eckstein N, Schneider V, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm. 2010;389(1):10–17.
   PubMedGoogle Scholar
• Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2004;53(4):329–336.
   PubMed Web of Science ®Google Scholar
• Auguste DT, Furman K, Wong A, et al. Triggered release of siRNA from poly (ethylene glycol)-protected, pH-dependent liposomes. J Control Release. 2008;130(3):266–274.
   PubMed Web of Science ®Google Scholar
• Schroeder A, Kost J, Barenholz Y. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids. 2009;162(1): 1–16.
   Web of Science ®Google Scholar
• Pashkovskaya A, Kotova E, Zorlu Y, et al. Light-triggered liposomal release: membrane permeabilization by photodynamic action. Langmuir. 2009;26(8):5726–5733.
   Web of Science ®Google Scholar
• Pradhan P, Giri J, Rieken F, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release. 2010;142(1):108–121.
   PubMed Web of Science ®Google Scholar
• Ong W, Yang Y, Cruciano AC, et al. Redox-triggered contents release from liposomes. J Am Chem Soc. 2008;130(44):14739–14744.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. J Pharm Biopharm. 2009;71(3):431–444.
   Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Chen ZG, et al. Advances of cancer therapy by nanotechnology. Cancer Res Treat. 2009;41(1):1–11.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26(5):1025–1058.
   PubMed Web of Science ®Google Scholar
• Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1):113–142.
   PubMedGoogle Scholar
• Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;28:797–800.
   Google Scholar
• Couvreur P, Kante B, Roland M, et al. Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci. 1979;68(12):1521–1524.
   PubMed Web of Science ®Google Scholar
• Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600–1603.
   PubMed Web of Science ®Google Scholar
• Gref R, Lück M, Quellec P, et al. ‘Stealth’corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3):301–313.
   PubMed Web of Science ®Google Scholar
• Tanford C. The hydrophobic effect: formation of micelles and biological membranes. 2nd ed. Malabar (Fla)7 Kreiger Publishing Company; 1991.
   Google Scholar
• Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells. Cancer Res. 2004;64(21):7668–7672.
   PubMed Web of Science ®Google Scholar
• Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci. 2008;105(7):2586–2591.
   PubMed Web of Science ®Google Scholar
• Aliabadi HM, Shahin M, Brocks DR, et al. Disposition of drugs in block copolymer micelle delivery systems. Clin Pharmacokinet. 2008;47(10):619–634.
   PubMed Web of Science ®Google Scholar
• Oerlemans C, Bult W, Bos M, et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res. 2010;27(12):2569–2589.
   PubMed Web of Science ®Google Scholar
• Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets. 2004;5(5):449–455.
   PubMed Web of Science ®Google Scholar
• Quintana A, Raczka E, Piehler L, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res. 2002;19:1310–6.
   PubMed Web of Science ®Google Scholar
• Ballauff M, Likos CN. Dendrimers in solution: insight from theory and simulation. Angew Chem Int Ed. 2004;43(23):2998–3020.
   PubMed Web of Science ®Google Scholar
• Boas U, Heegaard PM. Dendrimers in drug research. Chem Soc Rev. 2004;33(1):43–63.
   PubMed Web of Science ®Google Scholar
• Lee CC, MacKay JA, Fréchet JM, et al. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23(12):1517–1526.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Biotechnol. 2007;2(12):751–760.
   Google Scholar
• Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15(5):171–185.
   PubMed Web of Science ®Google Scholar
• Stasko NA, Johnson CB, Schoenfisch MH, et al. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules. 2007;8(12):3853–3859.
   PubMed Web of Science ®Google Scholar
• Ke W, Zhao Y, Huang R, et al. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci. 2008;97(6):2208–2216.
   PubMed Web of Science ®Google Scholar
• Chauhan AS, Jain NK, Diwan PV, et al. Solubility enhancement of indomethacin with poly (amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target. 2004;12(9-10):575–583.
   PubMed Web of Science ®Google Scholar
• Tripathi PK, Khopade AJ, Nagaich S, et al. Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie. 2002;57(4):261–264.
   PubMed Web of Science ®Google Scholar
• Hussain M, Shchepinov M, Sohail M, et al. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J Control Release. 2004;99(1):139–155.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Asthana A, Gupta U, et al. Tumour and dendrimers: a review on drug delivery aspects. J Pharm Pharmacol. 2008;60(6):671–688.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Eck PK, Regino CA, et al. Synthesis, characterization, and biological evaluation of integrin αvβ3-targeted PAMAM dendrimers. Mol Pharm. 2008;5(4):527–539.
   PubMedGoogle Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171–183.
   PubMed Web of Science ®Google Scholar
• Tiruppathi C, Song W, Bergenfeldt M, et al. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem. 1997;272(41):25968–25975.
   PubMed Web of Science ®Google Scholar
• Arruebo M, Galán M, Navascués N, et al. Development of magnetic nanostructured silica-based materials as potential vectors for drug-delivery applications. Chem Mater. 2006;18(7):1911–1919.
   Web of Science ®Google Scholar
• Frechet JMJ. Functional polymers: from plastic electronics to polymer-assisted therapeutics. Prog Polym Sci. 2005;30(8):844–857.
   Web of Science ®Google Scholar
• Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 2004;104(1):293–346.
   PubMed Web of Science ®Google Scholar
• Murphy CJ, Sau TK, Gole AM, et al. Anisotropic metal nanoparticles: synthesis, assembly, and optical applications. J Phys Chem B. 2005;109(29):13857–13870.
   PubMed Web of Science ®Google Scholar
• Bardhan R, Lal S, Joshi A, et al. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res. 2011;44(10):936–946.
   PubMed Web of Science ®Google Scholar
• Skrabalak SE, Chen J, Sun Y, et al. Gold nanocages: synthesis, properties, and applications. Acc Chem Res. 2008;41(12):1587–1595.
   PubMed Web of Science ®Google Scholar
• Link S, El-Sayed MA. Optical properties and ultrafast dynamics of metallic nanocrystals. Annu Rev Phys Chem. 2003;54(1): 331–366.
   Web of Science ®Google Scholar
• Kelly KL, Coronado E, Zhao LL, et al. The optical properties of metal nanoparticles: the influence of size, shape, and dielectric environment. J Phys Chem B. 2003;107(3):668–677.
   Web of Science ®Google Scholar
• Levy Y, Onuchic JN. Mechanisms of protein assembly: lessons from minimalist models. Acc Chem Res. 2006;39(2):135–142.
   PubMed Web of Science ®Google Scholar
• Yuan H, Fales AM, Vo-Dinh T. TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance. J Am Chem Soc. 2012;134(28):11358–11361.
   PubMed Web of Science ®Google Scholar
• Ali MR, Panikkanvalappil SR, El-Sayed MA. Enhancing the efficiency of gold nanoparticles treatment of cancer by increasing their rate of endocytosis and cell accumulation using rifampicin. J Am Chem Soc. 2014;136(12):4464–4467.
   PubMed Web of Science ®Google Scholar
• Jain S, Hirst DG, O’Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85 (1010):101–113.
   PubMed Web of Science ®Google Scholar
• Sam M, Hwang JH, Chanfreau G, et al. Hydroxyl radical is the active species in photochemical DNA strand scission by bis (peroxo) vanadium (V) phenanthroline. Inorg Chem. 2004;43(26):8447–8455.
   PubMed Web of Science ®Google Scholar
• Hirsch L, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci. 2003;100(23):13549–13554.
   PubMed Web of Science ®Google Scholar
• Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 2010;16(24):6139–6149.
   PubMed Web of Science ®Google Scholar
• Kauer-Dorner D, Pötter R, Resch A, et al. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial. Radiother Oncol. 2012;102(1):96–101.
   PubMed Web of Science ®Google Scholar
• Lowery AR, Gobin AM, Day ES, et al. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomedicine. 2006;1(2):149–154.
   PubMed Web of Science ®Google Scholar
• Kim ST, Chompoosor A, Yeh YC, et al. Dendronized gold nanoparticles for siRNA delivery. Small. 2012;8(21):3253–3256.
   PubMed Web of Science ®Google Scholar
• Joshi P, Chakraborti S, Ramirez-Vick JE, et al. The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells. Colloids Surf B Biointerfaces. 2012;95:195–200.
   PubMed Web of Science ®Google Scholar
• Kuo TR, Hovhannisyan VA, Chao YC, et al. Multiple release kinetics of targeted drug from gold nanorod embedded polyelectrolyte conjugates induced by near-infrared laser irradiation. J Am Chem Soc. 2010;132(40):14163–14171.
   PubMed Web of Science ®Google Scholar
• Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141(3):320–327.
   PubMed Web of Science ®Google Scholar
• El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006;239(1):129–135.
   PubMed Web of Science ®Google Scholar
• Wu P, Gao Y, Zhang H, et al. Aptamer-guided silver–gold bimetallic nanostructures with highly active surface-enhanced raman scattering for specific detection and near-infrared photothermal therapy of human breast cancer cells. Anal Chem. 2012;84(18):7692–7699.
   PubMed Web of Science ®Google Scholar
• Yang X, Liu X, Liu Z, et al. Near‐Infrared Light‐Triggered, Targeted Drug Delivery to Cancer Cells by Aptamer Gated Nanovehicles. Adv Mater. 2012;24(21):2890–2895.
   PubMed Web of Science ®Google Scholar
• Shi P, Qu K, Wang J, et al. pH-responsive NIR enhanced drug release from gold nanocages possesses high potency against cancer cells. Chem Commun. 2012;48(61):7640–7642.
   PubMed Web of Science ®Google Scholar
• Ma Y, Liang X, Tong S, et al. Gold Nanoshell Nanomicelles for Potential Magnetic Resonance Imaging, Light‐Triggered Drug Release, and Photothermal Therapy. Adv Funct Mater. 2013;23(7):815–822.
   Web of Science ®Google Scholar
• Gao Y, Li Y, Wang Y, et al. Controlled synthesis of multilayered gold nanoshells for enhanced photothermal therapy and SERS detection. Small. 2015;11(1):77–83.
   PubMed Web of Science ®Google Scholar
• Lin J, Wang S, Huang P, et al. Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano. 2013;7(6):5320–5329.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay N, Cai Z, Pignol JP, et al. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer. Mol Pharm. 2010;7(6):2194–2206.
   PubMedGoogle Scholar
• Koyama T, Shimura M, Minemoto Y, et al. Evaluation of selective tumor detection by clinical magnetic resonance imaging using antibody-conjugated superparamagnetic iron oxide. J Control Release. 2012;159(3):413–418.
   PubMed Web of Science ®Google Scholar
• Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med. 2012;3:77–85.
   PubMedGoogle Scholar
• Schütt W, Grüttner C, Häfeli U, et al. Applications of magnetic targeting in diagnosis and therapy—possibilities and limitations: a mini-review. Hybridoma. 1997;16(1):109–117.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18):3995–4021.
   PubMed Web of Science ®Google Scholar
• Dilnawaz F, Singh A, Mohanty C, et al. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials. 2010;31(13):3694–3706.
   PubMed Web of Science ®Google Scholar
• Jurgons R, Seliger C, Hilpert A, et al. Drug loaded magnetic nanoparticles for cancer therapy. J Phys Condens Matter. 2006;18(38):S2893–S2902.
   Web of Science ®Google Scholar
• Hu FX, Neoh KG, Kang ET. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials. 2006;27(33):5725–5733.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li L, Tang F, et al. Controlled drug delivery system based on magnetic hollow spheres/polyelectrolyte multilayer core–shell structure. J Nanosci Nanotechnol. 2006;6(9–10):3210–3214.
   PubMed Web of Science ®Google Scholar
• Ma Y, Manolache S, Denes F, et al. Plasma synthesis of carbon-iron magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. J Mater Eng Perform. 2006;15(3):376–382.
   Web of Science ®Google Scholar
• Zhang R, Wang X, Wu C, et al. Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology. 2006;17(14):3622.
   PubMed Web of Science ®Google Scholar
• Yang J, Lee H, Hyung W, et al. Magnetic PECA nanoparticles as drug carriers for targeted delivery: synthesis and release characteristics. J Microencapsul. 2006;23(2):203–212.
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Zhang ZR, Yang H, et al. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res. 2005;22(4):573–583.
   PubMed Web of Science ®Google Scholar
• Tadahikokubo TS, Shimose S, Nitta Y, et al. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol. 2001;18:121–125.
   PubMed Web of Science ®Google Scholar
• Jain TK, Morales MA, Sahoo SK, et al. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005;2(3):194–205.
   PubMed Web of Science ®Google Scholar
• Gazeau F, Lévy M, Wilhelm C. Optimizing magnetic nanoparticle design for nanothermotherapy. Nanomed. 2008;3:831–844.
   PubMed Web of Science ®Google Scholar
• Sanson C, Diou O, Thevenot J, et al. Doxorubicin loaded magnetic polymersomes: theranostic nanocarriers for MR imaging and magneto-chemotherapy. ACS Nano. 2011;5(2):1122–1140
   PubMed Web of Science ®Google Scholar
• Kim D, Lee N, Park M, et al. Synthesis of uniform ferrimagnetic magnetite nanocubes. J Am Chem Soc. 2008;131(2):454–455.
   Web of Science ®Google Scholar
• Lee N, Kim H, Choi SH, et al. Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets. Proc Natl Acad Sci. 2011;108(7):2662–2667.
   PubMed Web of Science ®Google Scholar
• Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007;13(1):95–99.
   PubMed Web of Science ®Google Scholar
• Zhao C, Rehman FU, Yang Y, et al. Bio-imaging and Photodynamic Therapy with Tetra Sulphonatophenyl Porphyrin (TSPP)-TiO2 Nanowhiskers: New Approaches in Rheumatoid Arthritis Theranostics. Sci Rep. 2015;5:1–11.
   Web of Science ®Google Scholar
• Setyawati MI, Tay CY, Leong DT. Mechanistic investigation of the biological effects of SiO2, TiO2, and zno nanoparticles on intestinal cells. Small. 2015;11(28):3458–3468.
   PubMed Web of Science ®Google Scholar
• Jin C, Tang Y, Yang FG, et al. Cellular toxicity of TiO2 nanoparticles in anatase and rutile crystal phase. Biol Trace Elem Res. 2011;141(1–3):3–15.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267–3285.
   PubMed Web of Science ®Google Scholar
• Pages BJ, Ang DL, Wright EP, et al. Metal complex interactions with DNA. Dalton Trans. 2015;44(8):3505–3526.
   PubMed Web of Science ®Google Scholar
• Ali A, Bhattacharya S. DNA binders in clinical trials and chemotherapy. Bioorg Med Chem. 2014;22(16):4506–4521.
   PubMed Web of Science ®Google Scholar
• Glasner H, Tshuva EY. C 1-Symmetrical Titanium (IV) Complexes of Salan Ligands with Differently Substituted Aromatic Rings: Enhanced Cytotoxic Activity. Inorg Chem. 2014;53(6):3170–3176.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wan Y, Wang Y, et al. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine. 2011;6:2321–6.
   PubMed Web of Science ®Google Scholar
• Hall MD, Mellor HR, Callaghan R, et al. Basis for design and development of platinum (IV) anticancer complexes. J Med Chem. 2007;50(15):3403–3411.
   PubMed Web of Science ®Google Scholar
• Schiesser S, Hackner B, Vrabel M, et al. Synthesis and DNA‐Damaging Properties of Cisplatin‐N‐Mustard Conjugates. European J Org Chem. 2015; (12):2654–2660.
   Web of Science ®Google Scholar
• Gao J, Liang G, Zhang B, et al. FePt@ CoS2 yolk-shell nanocrystals as a potent agent to kill HeLa cells. J Am Chem Soc. 2007;129(5):1428–1433.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu F, Andavan GT, et al. Carbon nanotube–DNA nanoarchitectures and electronic functionality. Small. 2006;2(11):1356–1365.
   PubMed Web of Science ®Google Scholar
• Xu C, Yuan Z, Kohler N, et al. FePt nanoparticles as an Fe reservoir for controlled Fe release and tumor inhibition. J Am Chem Soc. 2009;131(42):15346–15351.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang B, Sun S. Dumbbell-like Au − Fe3O4 nanoparticles for target-specific platin delivery. J Am Chem Soc. 2009;131(12):4216–4217.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883.
   PubMed Web of Science ®Google Scholar
• Akshintala S, Marcus L, Warren KE, et al. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatr Blood Cancer. 2015;62(4):603–610.
   PubMed Web of Science ®Google Scholar
• Weeks ME. The discovery of the elements. XVI. The rare earth elements. J Chem Educ. 1932;9(10):1751.
   Google Scholar
• Jakupec MA, Unfried P, Keppler BK. Pharmacological properties of cerium compunds. Rev Physiol Biochem Pharmacol. 2005;153:101–111.
   PubMed Web of Science ®Google Scholar
• Hirst SM, Karakoti A, Singh S, et al. Bio‐distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ Toxicol. 2013;28(2):107–118.
   PubMed Web of Science ®Google Scholar
• Xu C, Qu, X. Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications. NPG Asia Mater. 2014;6(3):e90.
   Web of Science ®Google Scholar
• Walkey C, Das S, Seal S, et al. Catalytic properties and biomedical applications of cerium oxide nanoparticles. Environ Sci Nano. 2015;2(1):33–53.
   PubMed Web of Science ®Google Scholar
• Colon J, Hsieh N, Ferguson A, et al. Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. Nanomedicine. 2010;6(5):698–705.
   PubMed Web of Science ®Google Scholar
• Xue Y, Luan Q, Yang D, et al. Direct evidence for hydroxyl radical scavenging activity of cerium oxide nanoparticles. J Phys Chem C. 2011;115(11):4433–4438.
   Web of Science ®Google Scholar
• Celardo I, De Nicola M, Mandoli C, et al. Ce3+ ions determine redox-dependent anti-apoptotic effect of cerium oxide nanoparticles. ACS Nano. 2011;5(6):4537–4549.
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen K, Ma JL, et al. Cerium oxide nanoparticles in cancer. Onco Targets Ther. 2014;7:835–840.
   PubMed Web of Science ®Google Scholar
• Ouyang Z, Mainali MK, Sinha N, et al. Potential of using cerium oxide nanoparticles for protecting healthy tissue during accelerated partial breast irradiation (APBI). Phys Med. 2016;32(4):631–635.
   PubMed Web of Science ®Google Scholar
• Khanna PK, More PV, Jawalkar JP, Bharate BG. Effect of reducing agent on the synthesis of nickel nanoparticles. Mater Lett. 2009;63(16):1384–1386.
   Web of Science ®Google Scholar
• Hossain MZ, Kleve MG. Nickel nanowires induced and reactive oxygen species mediated apoptosis in human pancreatic adenocarcinoma cells. Int J Nanomedicine. 2011;6:1475–1485.
   PubMed Web of Science ®Google Scholar
• Ahamed M, Alhadlaq HA. Nickel nanoparticle-induced dose-dependent cyto-genotoxicity in human breast carcinoma MCF-7 cells. Onco Targets Ther. 2014;7:269–280.
   PubMed Web of Science ®Google Scholar
• Guo D, Wu C, Hu H, et al. Study on the enhanced cellular uptake effect of daunorubicin on leukemia cells mediated via functionalized nickel nanoparticles. Biomed Mater. 2009;4(2):025013.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang Y, Huang B, et al. Evaluation of the antitumor activity by Ni nanoparticles with verbascoside. J Nanomater. 2013;2013:623497.
   Google Scholar
• Umaralikhan L, Jaffar MJM. Antibacterial and anticancer properties of NiO nanoparticles by co-precipitation method. J Adv Appl Sci Res. 2016;1(4):24–35.
   Web of Science ®Google Scholar
• Kelleher SL, McCormick NH, Velasquez V, et al. Zinc in specialized secretory tissues: roles in the pancreas, prostate, and mammary gland. Advances in Nutrition: Int Rev J. 2011;2(2):101–111.
   Google Scholar
• Hanley C, Layne J, Punnoose A, et al. Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles. Nanotechnology. 2008;19(29):295103.
   PubMed Web of Science ®Google Scholar
• Hanley C, Thurber A, Hanna C, et al. The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale Res Lett. 2009;4(12):1409–1420.
   PubMed Web of Science ®Google Scholar
• Akhtar MJ, Ahamed M, Kumar S, et al. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int J Nanomedicine. 2012;7:845–857.
   PubMed Web of Science ®Google Scholar
• Madani F, Lindberg S, Langel Ü, et al. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011;2011
   PubMedGoogle Scholar
• Papo N, Shahar M, Eisenbach L, et al. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem. 2003;278(23):21018–21023.
   PubMed Web of Science ®Google Scholar
• Asati A, Santra S, Kaittanis C, et al. Surface-charge-dependent cell localization and cytotoxicity of cerium oxide nanoparticles. ACS Nano. 2010;4(9):5321–5331.
   PubMed Web of Science ®Google Scholar
• Tripathy N, Ahmad R, Ko HA, et al. Enhanced anticancer potency using an acid-responsive ZnO-incorporated liposomal drug-delivery system. Nanoscale. 2015;7(9):4088–4096.
   PubMed Web of Science ®Google Scholar
• Xia T, Kovochich M, Brant J, et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 2006;6(8):1794–1807.
   PubMed Web of Science ®Google Scholar
• Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci. 2010;35(9):505–513.
   PubMed Web of Science ®Google Scholar
• Taccola L, Raffa V, Riggio C, et al. Zinc oxide nanoparticles as selective killers of proliferating cells. Int J Nanomed. 2011;6:1129–1140.
   PubMed Web of Science ®Google Scholar
• Wingett D, Louka P, Anders CB, et al. A role of ZnO nanoparticle electrostatic properties in cancer cell cytotoxicity. Nanotechnol Sci Appl. 2016;9:29–45.
   PubMed Web of Science ®Google Scholar
• Wang K, Xu JJ, Chen HY. A novel glucose biosensor based on the nanoscaled cobalt phthalocyanine–glucose oxidase biocomposite. Biosens Bioelectron. 2005;20(7):1388–1396.
   PubMed Web of Science ®Google Scholar
• Papis E, Rossi F, Raspanti M, et al. Engineered cobalt oxide nanoparticles readily enter cells. Toxicol Lett. 2009;189(3):253–259.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Dash SK, Ghosh T, et al. Surface modification of cobalt oxide nanoparticles using phosphonomethyl iminodiacetic acid followed by folic acid: a biocompatible vehicle for targeted anticancer drug delivery. Cancer Nanotechnol. 2013;4(4–5):103–116.
   PubMedGoogle Scholar
• Bouchard LS, Anwar MS, Liu GL, et al. Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. Proc Natl Acad Sci. 2009;106(11):4085–4089.
   PubMed Web of Science ®Google Scholar
• Sadjadi MS, Pourahmad A, Sohrabnezhad S, et al. Formation of NiS and CoS semiconductor nanoparticles inside mordenite-type zeolite. Mater Lett. 2007;61(14):2923–2926.
   Web of Science ®Google Scholar
• Ansari SM, Bhor RD, Pai KR, et al. Size and Chemistry Controlled Cobalt-Ferrite Nanoparticles and Their Anti-Proliferative Effect against the MCF-7 Breast Cancer Cells. ACS Biomater Sci Eng. 2016;2(12):2139–2152.
   PubMed Web of Science ®Google Scholar
• Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6(4):463–477.
   PubMed Web of Science ®Google Scholar
• Wang HY, Hua XW, Wu FG, et al. Synthesis of ultrastable copper sulfide nanoclusters via trapping the reaction intermediate: potential anticancer and antibacterial applications. ACS Appl Mater Interfaces. 2015;7(13):7082–092.
   PubMed Web of Science ®Google Scholar
• Lee T, El-Said WA, Min J, et al. Multifunctional DNA-based biomemory device consisting of ssDNA/Cu heterolayers. Biosens Bioelectron. 2011;26(5):2304–2310.
   PubMed Web of Science ®Google Scholar
• Meghana S, Kabra P, Chakraborty S, et al. Understanding the pathway of antibacterial activity of copper oxide nanoparticles. RSC Adv. 2015;5(16):12293–12299.
   Web of Science ®Google Scholar
• Fahmy B, Cormier SA. Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells. Toxicol In Vitro. 2009;23(7):1365–1371.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zi XY, Su J, et al. Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells. Int J Nanomedicine. 2012;7:2641–2652.
   PubMed Web of Science ®Google Scholar
• Laha D, Pramanik A, Maity J, et al. Interplay between autophagy and apoptosis mediated by copper oxide nanoparticles in human breast cancer cells MCF7. Biochim Biophys Acta. 2014;1840(1):1–9.
   PubMed Web of Science ®Google Scholar
• Simstein R, Burow M, Parker A, et al. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med. 2003;228(9):995–1003.
   Web of Science ®Google Scholar
• Fu LL, Yang Y, Xu HL, et al. Identification of novel caspase/autophagy‐related gene switch to cell fate decisions in breast cancers. Cell Prolif. 2013;46(1):67–75.
   PubMed Web of Science ®Google Scholar
• Hanagata N, Zhuang F, Connolly S, et al. Molecular responses of human lung epithelial cells to the toxicity of copper oxide nanoparticles inferred from whole genome expression analysis. ACS Nano. 2011;5(12):9326–9338.
   PubMed Web of Science ®Google Scholar
• Laurent A, Nicco C, Chéreau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65(3):948–956.
   PubMed Web of Science ®Google Scholar
• Foldbjerg R, Dang DA, Autrup H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol. 2011;85(7):743–750.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Han JW, Eppakayala V, et al. Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells. Biomed Res Int. 2013; 2013:1–10
   Web of Science ®Google Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Sierra-Rivera CA, et al. Antitumor activity of colloidal silver on MCF-7 human breast cancer cells. J Exp Clin Cancer Res. 2010;29(1):148.
   PubMedGoogle Scholar
• Sanpui P, Chattopadhyay A, Ghosh SS. Induction of apoptosis in cancer cells at low silver nanoparticle concentrations using chitosan nanocarrier. ACS Appl Mater Interfaces. 2011;3(2):218–228
   PubMed Web of Science ®Google Scholar
• Hsin YH, Chen CF, Huang S, et al. The apoptotic effect of nanosilver is mediated by a ROS-and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol Lett. 2008;179(3):130–139.
   PubMed Web of Science ®Google Scholar
• Foldbjerg R, Olesen P, Hougaard M, et al. PVP-coated silver nanoparticles and silver ions induce reactive oxygen species, apoptosis and necrosis in THP-1 monocytes. Toxicol Lett. 2009;190(2):156–162.
   PubMed Web of Science ®Google Scholar
• Ahmad P, Sarwat M, Sharma S. Reactive oxygen species, antioxidants and signaling in plants. J Plant Biol. 2008;51(3):167–173.
   Web of Science ®Google Scholar
• Sriram MI, Kanth SBM, Kalishwaralal K, et al. Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model. Int J Nanomedicine. 2010;5(1):753–762.
   PubMed Web of Science ®Google Scholar
• Vernhet L, Allain N, Le Vée M, et al. Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J Pharmacol Exp Ther. 2003;304(1):145–155.
   PubMed Web of Science ®Google Scholar
• Emadi A, Gore SD. Arsenic trioxide—an old drug rediscovered. Blood Rev. 2010;24(4):191–199.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012;26(3):433–442.
   PubMed Web of Science ®Google Scholar
• Chen GC, Guan LS, Hu WL, et al. Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Res. 2001;22(2A):633–638.
   Web of Science ®Google Scholar
• Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004;93(1):173–187.
   PubMed Web of Science ®Google Scholar
• Wang X, Gao P, Long M, et al. Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011;28(4):1225–1254.
   PubMed Web of Science ®Google Scholar
• Davison K, Mann KK, Miller WH. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002;39(2):3–7.
   PubMed Web of Science ®Google Scholar
• Xia J, Li Y, Yang Q, et al. Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci. 2012;13(8):9627–9641.
   PubMed Web of Science ®Google Scholar
• Du J, Zhou N, Liu H, et al. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Yang L, et al. Arsenic trioxide induces the apoptosis of human breast cancer MCF-7 cells through activation of caspase-3 and inhibition of HERG channels. Exp Ther Med. 2011;2(3):481–486.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/record/NCT01190982 (Acessesd on 19-12, 2016)
   Google Scholar
• https://clinicaltrials.gov/show/NCT01151384 (Acessesd on 19-12, 2016)
   Google Scholar
• Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv. 2011;2012:1–10.
   Google Scholar
• Saif MW. MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer. JOP. 2014;15(3):278–279.
   PubMedGoogle Scholar
• Awada A, Bondarenko IN, Bonneterre J, et al. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol. 2014;25(4):824–831.
   PubMed Web of Science ®Google Scholar
• Cattaneo AG, Gornati R, Sabbioni E, et al. Nanotechnology and human health: risks and benefits. J Appl Toxicol. 2010;30(8):730–744.
   PubMed Web of Science ®Google Scholar
• Zagar TM, Vujaskovic Z, Formenti S, et al. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014;30(5):285–294.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/record/NCT02213744 (Accessed on -12, 2016)
   Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1(3):297–315.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/record/NCT00876486(Accessed on 19-12, 2016)
   Google Scholar
• Booser DJ, Perez-Soler R, Cossum P, et al. Phase I study of liposomal annamycin. Cancer Chemother Pharmacol. 2000;46(5):427–432.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006;23(7):1417–1450.
   PubMed Web of Science ®Google Scholar
• Vivek R, Thangam R, Nipunbabu V, et al. Oxaliplatinchitosan nanoparticles induced intrinsic apoptotic signaling pathway: A “smart” drug delivery system to breast cancer cell therapy. Int J Biol Macromol. 2014;65:289–297.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/record/NCT01644890 (Accessed on 19-12, 2016)
   Google Scholar
• Liu F, Park JY, Zhang Y, et al. Targeted cancer therapy with novel high drug‐loading nanocrystals. J Pharm Sci. 2010;99(8):3542–3551.
   PubMed Web of Science ®Google Scholar
• Kono K, Mimura K, Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis. 2013;4(6):e688.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/record/NCT00075413 (Accessed on 19-12, 2016)
   Google Scholar